Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRB | O95718 | 5/20 | 0.75 |
| ▸ | ESR1 | P03372 | 10/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.64 |
| ▸ | ESRRG | P62508 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | HTR6 | P50406 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | PGR | P06401 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.64 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.64 |
| ▸ | EGFR | P00533 | 1/20 | 0.64 |
| ▸ | GBA1 | P04062 | 1/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10016265 | 0.86 | ESRRB (1.00) | ESRRBESR1ESR2ESRRGMAPT | |
| SCHEMBL10047996 | 0.86 | ESRRB (1.00) | ESRRBESR1ESR2ESRRGMAPT | |
| SCHEMBL20224018 | 0.85 | ESR1 (0.78) | ESRRBESR1ESR2ESRRGMAPT | |
| SCHEMBL638890 | 0.83 | ESRRB (1.00) | ESRRBESR1ESR2ESRRGMAPT | |
| SCHEMBL638891 | 0.83 | ESRRB (1.00) | ESRRBESR1ESR2ESRRGMAPT | |
| SCHEMBL638915 | 0.83 | ESRRB (1.00) | ESRRBESR1ESR2ESRRGMAPT | |
| SCHEMBL31336712 | 0.81 | ESR1 (0.58) | ESRRBESR1ESR2ESRRGMEN1 | |
| SCHEMBL17164708 | 0.80 | ESR1 (0.89) | ESRRBESR1ESR2ESRRGMAPT | |
| SCHEMBL17164697 | 0.80 | ESR1 (0.89) | ESRRBESR1ESR2ESRRGMAPT | |
| SCHEMBL10016281 | 0.79 | ESRRB (0.88) | ESRRBESR1ESR2ESRRGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780063-B2 | Method for the treatment or prevention of lower urinary tract symptoms | HORMOS MEDICAL LTD. (FI) | 2020-09-22 | — | — | US | disclosed |
| US-20180256513-A1 | METHOD FOR THE TREATMENT OR PREVENTION OF LOWER URINARY TRACT SYMPTOMS | HORMOS MEDICAL LTD. | 2018-09-13 | — | — | US | disclosed |
| US-9993442-B2 | Method for the treatment or prevention of lower urinary tract symptoms | HORMOS MEDICAL LTD. (FI) | 2018-06-12 | — | — | US | disclosed |
| US-9873670-B2 | Arylquinoline and analog compounds and use thereof to treat cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2018-01-23 | — | — | US | disclosed |
| EP-2673250-B1 | STILBENE ANALOGS AND METHODS OF TREATING CANCER | UNIV KENTUCKY RES FOUND (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160332971-A1 | ARYLQUINOLINE, ARYLQUINOLONE AND ARYLTHIOQUINOLONE DERIVATIVES AND USE THEREOF TO TREAT CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-11-17 | — | — | US | disclosed |
| US-20160280652-A1 | ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-09-29 | — | — | US | disclosed |
| CN-105622431-A | Stilbene analogs and methods of treating cancer | UNIV KENTUCKY | 2016-06-01 | — | — | CN | disclosed |
| US-20150352059-A1 | METHOD FOR THE TREATMENT OR PREVENTION OF LOWER URINARY TRACT SYMPTOMS | HORMOS MEDICAL CORPORATION (FI) | 2015-12-10 | — | — | US | disclosed |
| US-9132102-B2 | Stilbene analogs and methods of treating cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| EP-1766025-A1 | PORCINE SULFOTRANSFERASE 2A1 POLYNUCLEOTIDE SEQUENCE, PROTEIN, AND METHODS OF USE FOR SAME | UNIVERSITY OF GUELPH (CA) | 2007-03-28 | — | — | EP | disclosed |
| EP-1718287-A1 | METHOD FOR TREATMENT OR PREVENTION OF OSTEOPOROSIS IN INDIVIDUALS WITH HIGH BONE TURNOVER | Hormos Medical Ltd. (FI) | 2006-11-08 | — | — | EP | disclosed |
| CN-1798723-A | Method for treating or preventing lower urinary tract symptoms | HORMOS MEDICAL CORP (FI) | 2006-07-05 | — | — | CN | disclosed |
| EP-1636159-A1 | METHOD FOR THE TREATMENT OR PREVENTION OF LOWER URINARY TRACT SYMPTOMS | Hormos Medical Ltd. (FI) | 2006-03-22 | — | — | EP | disclosed |
| US-20060024708-A1 | Porcine sulfotransferase 2A1 polynucleotide sequence, protein, and methods of use for same | UNIVERSITY OF GUELPH (CA) | 2006-02-02 | — | — | US | disclosed |
| WO-2005123922-A1 | PORCINE SULFOTRANSFERASE 2A1 POLYNUCLEOTIDE SEQUENCE, PROTEIN, AND METHODS OF USE FOR SAME | UNIVERSITY OF GUELPH (CA) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005079776-A1 | METHOD FOR TREATMENT OR PREVENTION OF OSTEOPOROSIS IN INDIVIDUALS WITH HIGH BONE TURNOVER | HORMOS MEDICAL LTD. (FI) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187302-A1 | Method for treatment or prevention of osteoporosis in individuals with high bone turnover | HORMOS MEDICAL CORPORATION (FI) | 2005-08-25 | — | — | US | disclosed |
| WO-2004108645-A1 | METHOD FOR THE TREATMENT OR PREVENTION OF LOWER URINARY TRACT SYMPTOMS | HORMOS MEDICAL CORPORATION (FI) | 2004-12-16 | — | — | WO | disclosed |
| US-20040248989-A1 | Method for the treatment or prevention of lower urinary tract symptoms | HORMOS MEDICAL LTD. (FI) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280652-A1 | ARYLQUINOLINE AND ANALOG COMPOUNDS AND USE THEREOF TO TREAT CANCER | CASP4, BAD, BID | ESRRB 1743/4885ESR1 726/4885ESR2 1004/4885 |
| US-20160332971-A1 | ARYLQUINOLINE, ARYLQUINOLONE AND ARYLTHIOQUINOLONE DERIVATIVES AND USE THEREOF TO TREAT CANCER | CASP4, PARP14, API5 | ESRRB 1730/4885ESR1 1008/4885ESR2 1149/4885 |
| US-20050187302-A1 | Method for treatment or prevention of osteoporosis in individuals with high bone turnover | SOST, PTH1R, SHBG | ESRRB 5/4885ESR1 13/4885ESR2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.